Sunday, March 29, 2020 10:51:32 AM
For those who don't work in science-related industry, here are a few key steps required to get the ball rolling and get some scientific data aka the stuff that is going to send this stock to the moon... and I am not going to waste a lot of time repeating what's spelled out very clearly in the BioPub interview Algernon did because that was very clear and anyone investing here should have watched that.
1. Pre-clinical research: As stated in BioPub interview, having data in animal studies that shows your drug has therapeutic efficacy (aka it actually treats the disease of interest). We have this done. As Smoki pointed out... one aspect of our drug pipeline is for idiopathic pulmonary fibrosis and chronic cough... and our lead outperforms the best drug big pharma has... you better not kid yourself, big pharma is watching, they definitely saw the headlines... they always watch for competition...
2. Safety and early phase trials: these usually cost hundreds of millions. We are using repurposed drugs. We have patents protecting Ifenprodil for respiratory diseases. We are saving hundreds of millions. We are doing some FDA-registered clinical trial testing in the USA (FDA registered Algernon trial. We will show it's safe for injection by IV. We will show it works for acute lung injury and cough.
3. Clinical trials: Everybody investing here wants to score big and see the share price in the several dollars range. That's obvious. So how do we get that? Solid scientific data that shows our drug outperforms others (e.g. chronic cough and idiopathic pulmonary fibrosis). Or, our drug saves lives from the lung injury causes by COVID. We have NOVOTECH which is a certified CRO which is going to be running our trials. We have funding. We have NOVOTECH investing there own money (skin in the game) in Algernon. FDA and medical regulatory authorities in Australia and South Korea will fast track ifenprofil for COVID-19 related use. 2-4 weeks is reasonable to know how the drug is working, I agree. However, the number one key limiting factor to determine when the trial starts, is when Mark Williams finishes the ethics approval and study protocol. That's the time consuming step.. However, I am of the belief he's working his butt off. Look at all the news releases. Look at the recent FDA trial registration. I think these fellas know there is money to be made and they aren't playing around. Get ready for blast off.
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM